EarningsAytu reported F3Q25 results with total revenue of $18.5M, exceeding the estimate of $13.7M.
Financial PerformanceF3Q25 was the 3rd straight quarter of positive net income and the 8th straight of positive Adjusted EBITDA.
Product LaunchThe recently launched MDD therapy, Auvelity by Axsome Therapeutics, reached approximately $400M in sales within about 2.5 years, which is a positive indicator for EXXUA’s launch potential.